NLS Pharmaceutics (NLSP) Regains Nasdaq Compliance

NLS Pharmaceutics Ltd. (Nasdaq: NLSP)(Nasdaq: NLSPW) today announced that it has received notice from the Nasdaq Stock Market LLC ("NASDAQ") informing the Company that it has regained full compliance with the bid price requirement in Listing Rule 5550(a)(2) and the equity requirement in Listing Rule 5550(b)(1).

"We are pleased to report that Nasdaq has recognized our full compliance with their listing requirements," said Alex Zwyer, Chief Executive Officer of NLS Pharmaceutics. "Their confirmation follows our successful efforts to improve our balance sheet, including raising new capital and implementing a reverse share split."

You May Also Be Interested In

• Deere conference call: 2027 orders up mid-single digits from last year)
• Quanome Technologies forms quantum advisory council and network
• NACCO Industries (NC) Declares $0.2625 Quarterly Dividend; 2.6% Yield